For Immediate Release
Chicago, IL – October 20, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include
Amazon.com ( AMZN Quick Quote AMZN - Free Report) , The Home Depot ( HD Quick Quote HD - Free Report) , Sanofi ( SNY Quick Quote SNY - Free Report) , Intel ( INTC Quick Quote INTC - Free Report) and American Tower ( AMT Quick Quote AMT - Free Report) . Here are highlights from Monday’s Analyst Blog: Top Stock Reports for Amazon, Home Depot and Sanofi
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, The Home Depot and Sanofi. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>> Amazon shares have lost some ground lately, but the stock has been a standout performer in the year-to-date period (+77.1% vs. +8.2% for the S&P 500 index) on the back of Amazon's leverage to the boost in digital sales as a result of the pandemic.
Additionally, solid Prime momentum owing to ultrafast delivery services and expanding content portfolio remains a tailwind. Further, a strong adoption rate of AWS is aiding the company’s cloud dominance. Moreover, expanding the AWS portfolio is contributing well. Additionally, improving Alexa skills and features are positives.
Also, expanding smart home products offerings are tailwinds. However, accelerating coronavirus related expenses might hurt the company’s profitability in the near term. Also, foreign exchange headwinds and rising cloud competition are concerns.
) read the full research report on Amazon here >>>
Home Depot have gained +21.5% over the past year against the Zacks Retail Building Products industry’s rise of 29.6%. The Zacks analyst believes that Home Depot’s interconnected retail strategy and underlying technology infrastructure have boosted web traffic in the past several months.
The company posted better-than-expected top and bottom-line results in the second-quarter fiscal 2020, despite the looming impacts of the coronavirus outbreak. Sales gains were attributed to its robust and flexible interconnected infrastructure, which helped it quickly adapt to the changing customer preferences amid the coronavirus pandemic.
It also gained from strong growth in its Pro and DIY customer categories. Notably, DIY sales outpaced Pro sales growth in the fiscal second quarter owing to rise in home improvement projects. However, it incurred additional costs related to the coronavirus pandemic which partly deleveraged expenses.
) read the full research report on Home Depot here >>> Sanofi shares have gained +4.1% over the past six months against the Zacks Large Cap Pharmaceuticals industry’s fall of -0.2%. The Zacks analyst believes that its R&D pipeline is strong and cost-savings and efficiency initiatives are supporting the bottom-line.
Sanofi’s Specialty Care segment is on a strong footing, particularly with regular label expansion of Dupixent. The drug has, in a very short time, become Sanofi’s key top-line driver. Sanofi possesses one of the world’s leading vaccine operations.
However, headwinds include weak performance of the Diabetes unit, generic competition for many drugs and slower-than-expected uptake of core products like Praluent. COVID-19 resulted in slowdown of new patient additions, deferral of procedures and some vaccinations, and lower in-pharmacy traffic in Q2. Estimates have gone down slightly ahead of Q3 earnings. Sanofi has a mixed record of earnings surprise in the recent quarters.
) read the full research report on Sanofi here >>>
Other noteworthy reports we are featuring today include Intel and American Tower.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>
Join us on Facbook:
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.